Table 2 Input data used in our model
Variable | Value | Source |
|---|---|---|
Vaccine administration cost | €6.16 | [21] |
QIVe acquisition cost | €6.55 | NHS transfer price |
QIVc acquisition cost | €7.50 | NHS transfer price |
Costs of prescribed influenza drugs | €20.78 | [22] |
Costs of influenza drugs without prescription | €11.34 | [23] |
Cost of GP visit | €20.66 | Italian national tariff |
Vaccination coverage among HCWs | 30% | Assumption |
Influenza attack rate in an unvaccinated cohort | 4.4% | [24] |
Number of working days lost (average duration of influenza) | 2 | Italian National Institute of Health, 2023 [28] |
HCWs who develop influenza symptoms | 66.90% | [25] |
Vaccine effectiveness (QIVe) | 45.91% | [25] |
Vaccine effectiveness (QIVc) | 56.91% | |
Indirect costs and fiscal impact | ||
Total working hours/HCW | 2112 | [20] |
Total working hours/week | 44 | [14] |
Hourly cost | €36.50 | Calculated |
Taxable hourly fixed part | €30.30 | Calculated |
Taxable hourly variable part | €6.21 | Calculated |
Total weekly taxable income | €1606.04 | Calculated |
Total annual taxable income | €77 089.83 | Calculated |
Number of working hours lost owing to influenza | 16 | [14] |
Working hours considering one episode of influenza/HCW | 2096 | [14] |
Impact of influenza complications on total potential man-hours | 0 | [14] |
% HCWs with influenza complications | 0% | Assumption |
Total annual taxable income of a HCW who contracts influenza | €76 990.55 | Calculated |
Personal income tax rates (Italy) | ||
€15 000 | 23.00% | [29] |
€28 000 | 27.00% | [29] |
€55 000 | 38.00% | [29] |
€75 000 | 41.00% | [29] |
> €75 000 | 43.00% | [29] |
Annual revenue (no influenza) | €26 318.63 | Calculated |
Annual revenue (with influenza) | €26 275.94 | Calculated |
Tax impact | €42.69 | Calculated |
Annual cost of productivity loss per HCW | €584.01 | Calculated |